Stay updated on Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedPublications are described as auto-filled from PubMed, and the page revision was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check26 days agoChange DetectedThe page no longer displays a site-wide government funding/operating status notice, which does not affect the trial data or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check47 days agoChange DetectedResults for the RELIVE study have been posted on the page, and the Study Record Dates now show a Results First Posted date of 2021-06-02.SummaryDifference0.2%

- Check69 days agoChange DetectedMajor update: new operating-status notice and a v3.2.0 release; removal of the old v3.1.0 tag.SummaryDifference2%

- Check76 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check90 days agoChange DetectedUpdated the location from Bourgoin-Jallieu, France, 38302 to Bourgoin, France, 38302 and bumped the revision from v3.0.1 to v3.0.2; removed the 'Back to Top' link. This is a minor editorial change with no impact on pricing, stock, or time-slot availability.SummaryDifference0.2%

Stay in the know with updates to Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial page.